{"id":1898,"date":"2026-04-27T12:00:28","date_gmt":"2026-04-27T12:00:28","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/04\/27\/eu-experts-back-tolebrutinib-approval-for-spms-patients-with-no-relapses\/"},"modified":"2026-04-27T12:00:28","modified_gmt":"2026-04-27T12:00:28","slug":"eu-experts-back-tolebrutinib-approval-for-spms-patients-with-no-relapses","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/04\/27\/eu-experts-back-tolebrutinib-approval-for-spms-patients-with-no-relapses\/","title":{"rendered":"EU experts back tolebrutinib approval for SPMS patients with no relapses"},"content":{"rendered":"<p><a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/04\/27\/eu-experts-urge-approval-tolebrutinib-brand-name-cenrifki-nonrelapsing-spms\/\" title=\"EU experts back tolebrutinib approval for SPMS patients with no relapses\" rel=\"nofollow\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"534\" src=\"https:\/\/multiplesclerosisnewstoday.com\/wp-content\/uploads\/2026\/04\/iStock-940980120-800x534.jpg\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"A tablet with an image of the European Union flag is surrounded by prescription medications and a stethoscope.\" style=\"margin: auto;margin-bottom: 15px;max-width: 100%\" data-wp-pid=\"161614\" \/><\/a><\/p>\n<p>Regulators in the European Union are recommendeding that tolebrutinib be approved as a treatment for people with secondary progressive multiple sclerosis (SPMS) who have not experienced a relapse in the last two years. That new positive opinion was issued by the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP), a regulatory body [&#8230;]<\/p>\n<p>The post <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/04\/27\/eu-experts-urge-approval-tolebrutinib-brand-name-cenrifki-nonrelapsing-spms\/\">EU experts back tolebrutinib approval for SPMS patients with no relapses<\/a> appeared first on <a href=\"https:\/\/multiplesclerosisnewstoday.com\">Multiple Sclerosis News Today<\/a>.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/04\/27\/eu-experts-urge-approval-tolebrutinib-brand-name-cenrifki-nonrelapsing-spms\/\" rel=\"nofollow noopener\" target=\"_blank\">multiplesclerosisnewstoday.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regulators in the European Union are recommendeding that tolebrutinib be approved as a treatment for people with secondary progressive multiple sclerosis (SPMS) who have not experienced a relapse in the last two years. That new positive opinion was issued by the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP), a regulatory body&#8230;<\/p>\n","protected":false},"author":0,"featured_media":1899,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1898","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1898"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1898\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/1899"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}